GLP-1 receptor agonists, originally approved for the management of type 2 diabetes, emerged as promising anti-obesity medications after demonstrating significant weight reduction alongside improved glycemic control. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.